发明名称 |
IDENTIFICATION OF UNIQUE BINDING INTERACTIONS BETWEEN CERTAIN ANTIBODIES AND THE HUMAN B7.1 AND B7.2 CO-STIMULATORY ANTIGENS |
摘要 |
<p>The present invention relates to the identification of antibodies which are specific to human B7.1 antigen (CD80) and which are capable of inhibiting the binding of B7.1 to a CD28 receptor and which are not capable of inhibiting the binding of B7.1 to a CTLA-4 receptor. Two of these antibodies, 16C10 and 7C10, significantly inhibit the production of IL-2, in spite of the existence of a second activating ligand B7.2 (CD86). Blocking of the primary activation signal between CD28 and B7.1 (CD80) with these antibodies while allowing the unimpaired or coincident interaction of CTLA-4 and B7.1 and/or B7.2 represents a combined antagonistic effect on positive co-stimulation with an agonistic effect on negative signalling. These antibodies may be used as specific immunosuppressants, e.g., for the treatment of autoimmune diseases and to prevent organ transplant rejection.</p> |
申请公布号 |
WO9819706(A1) |
申请公布日期 |
1998.05.14 |
申请号 |
WO1997US19906 |
申请日期 |
1997.10.29 |
申请人 |
IDEC PHARMACEUTICALS CORPORATION |
发明人 |
ANDERSON, DARRELL, R.;HANNA, NABIL;BRAMS, PETER |
分类号 |
C12N15/02;A61K38/00;A61K39/395;A61P3/10;A61P7/04;A61P7/06;A61P17/06;A61P19/02;A61P25/00;A61P27/14;A61P29/00;A61P37/00;A61P37/06;C07K16/28;(IPC1-7):A61K39/395;C07K16/18 |
主分类号 |
C12N15/02 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|